Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder

Journal of Clinical Psychiatry

Volumn 62, Issue 11, 2001, Pages 888-893

  Meoni, P ^a   Salinas, E ^a   Brault, Y ^a   Hackett, D ^a  

^a Wyeth Ayerst Research European CR and D Department   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DIAZEPAM; PLACEBO; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; BEHAVIOR; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HOSTILITY; HUMAN; INTELLIGENCE; MAJOR CLINICAL STUDY; MUSCLE TONE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION;

EID: 0035196266     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n1109     Document Type: Article

References (26)

1. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey
2. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: A valid diagnostic entity?
3. Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam
4. The clinical presentation of generalized anxiety in primary care settings: Practical concepts of classification and management
5. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients
6. Bromazepam and diazepam in generalized anxiety: A placebo-controlled study with measurement of drug plasma concentrations
7. Buspirone and diazepam in anxiety: A controlled study
8. Evaluation of buspirone as an antianxiety agent: Buspirone and diazepam versus placebo
9. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder
10. The assessment of anxiety states by rating
11. The brief scale for anxiety: A subdivision of the comprehensive psychopathological rating scale
12. Effect size as a measure of symptom-specific drug change in clinical trials
13. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials
14. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: A meta-analysis
15. A meta-analysis of the effects of venlafaxine on anxiety associated with depression
16. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety
17. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
18. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
19. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomised controlled trial
20. Controlling for the placebo response rate: A methodological approach to data from double-blind studies with high placebo reponse
21. A dose-response, 6 month evaluation of venlafaxine extended-release in outpatients with generalized anxiety disorder
22. Outpatient treatment of neurotic depression: Medication and group psychotherapy
23. Rater and patient characteristics associated with rater differences in psychiatric scale ratings
24. The Hamilton anxiety scale: Evaluation of homogeneity and inter-observer reliability in patients with depressive disorders
25. Analysis of individual symptoms in generalized anxiety: A pooled, multistudy, double-blind evaluation of buspirone